By Independent News Roundup
A major new peer-reviewed scoping review by Dr. Claudia Chaufan et al. analyzed 109 published studies on COVID-19 vaccination and autoimmune disease — and the findings are worrisome.
Across dozens of countries and all major vaccine platforms, the same pattern emerged:
COVID-19 vaccination is repeatedly associated with autoimmune flares, relapses, and entirely new autoimmune diseases
— including multiple sclerosis, lupus, type 1 diabetes, rheumatoid
arthritis, Graves’ disease, Hashimoto’s thyroiditis, and more.
More than half the studies suggested a causal link.

The authors examined 109 published studies spanning every major research design used in autoimmune safety literature. This diversity strengthens the signal: the same autoimmune patterns appear regardless of methodology, country, or vaccine platform.
36 out of 109 studies (33.1%)
Included flares, relapses, worsening symptoms, and new-onset MS.
31 out of 109 studies (28.4%)
Included cutaneous lupus flares, multi-organ lupus onset, severe pediatric SLE, lupus myocarditis, etc.
16 out of 109 studies (14.7%)
Included abrupt-onset autoimmune diabetes, DKA, beta-cell failure, hyperglycemia, and worsening glycemic control.
13 out of 109 studies (11.9%)
Included both flares and new-onset hyperthyroidism, often within days to weeks post-vaccination.
13 out of 109 studies (11.9%)
Included severe RA flares, joint swelling, EBV reactivation, and new-onset RA.
Included within the autoimmune thyroiditis pool.
No flares were documented — but new-onset Hashimoto’s cases were reported.
11 out of 109 studies (10.1%)
Reported
clusters or overlapping conditions (e.g., SLE + antiphospholipid
syndrome, MS + autoimmune antibody emergence, thyroiditis + diabetes).
Taken together, these data form the most comprehensive map to date of autoimmune outcomes following COVID-19 vaccination. Across 109 studies spanning every major autoimmune category, researchers documented: recurrent autoimmune flares, new diagnoses in already autoimmune-vulnerable patients, and entirely new autoimmune diseases in previously healthy people.
The signal appears across continents, across vaccine platforms, and across every study design — including case reports, case series, observational cohorts, and controlled data.
This is a safety signal that can no longer be dismissed or minimized.
Epidemiologist and Foundation Administrator, McCullough Foundation
Support our mission: mcculloughfnd.org
Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content.